GAN Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about GAN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 217 trials

Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled175 locationsNCT06172296
Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

ProlactinomaCushing DiseasePanhypopituitarism+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2,000 enrolled1 locationNCT00001595
Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled400 locationsNCT05675410
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled215 locationsNCT06935357
Recruiting
Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Pyoderma Gangrenosum
Boehringer Ingelheim90 enrolled95 locationsNCT06624670
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Not Applicable

The Treatment of Painful Diabetic Neuropathy With Diet

Peripheral Neuropathy With Type 2 DiabetesPainful Diabetic Neuropathy (PDN)Vegan Diet
AdventHealth40 enrolled1 locationNCT07509671
Recruiting

Genome Transplant Dynamics

Thoracic Organ Transplantation
National Heart, Lung, and Blood Institute (NHLBI)991 enrolled6 locationsNCT02423070
Recruiting
Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled8 locationsNCT07146906
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

GM1 GangliosidosisGM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.147 enrolled37 locationsNCT07054515
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Gangliosidoses, GM2Gangliosidosis, GM1
Azafaros A.G.75 enrolled36 locationsNCT07082543
Recruiting
Phase 2

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

GerminomaBasal Ganglia GerminomaDiabetes Insipidus+3 more
Children's Oncology Group240 enrolled107 locationsNCT06368817
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting

Clinical and Laboratory Study of Methylmalonic Acidemia

Inborn Errors of MetabolismOrganic AcidemiaMethylmalonic Acidemia
National Human Genome Research Institute (NHGRI)2,275 enrolled3 locationsNCT00078078
Recruiting

Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics

Malignant NeoplasmOrgan Damage
Hebei Medical University Fourth Hospital2,000 enrolled1 locationNCT07131007
Recruiting
Phase 2

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

GM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.21 enrolled3 locationsNCT07399704
Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376